Virax Biolabs Group Limited (VRAX)

NASDAQ: VRAX · Real-Time Price · USD

0.215

+0.008 (3.62%)

At close: Mar 6, 2026, 4:00 PM EST

0.216

+0.001 (0.56%)

After-hours: Mar 6, 2026, 6:52 PM EST

Virax Biolabs Group Employees

Virax Biolabs Group had 19 employees as of March 31, 2025. The number of employees increased by 2 or 11.76% compared to the previous year.

Employees

19

Change (1Y)

2

Growth (1Y)

11.76%

Revenue / Employee

$157

Profits / Employee

-$297,031

Market Cap

1.59M

Employees Chart

Employees History

Date	Employees	Change	Growth
Mar 31, 2025	19	2	11.76%
Mar 31, 2024	17	6	54.55%
Mar 31, 2023	11	6	120.00%
Mar 31, 2022	5	-	-

Related Stocks

Company Name	Employees
Lyra Therapeutics	30
Azitra	12
Ensysce Biosciences	8
CDT Equity	6
CNS Pharmaceuticals	5
Adial Pharmaceuticals	5
Artelo Biosciences	5
XORTX Therapeutics	3

Employee Rankings

VRAX News

3 months ago - Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement - PRNewsWire
3 months ago - Virax Biolabs Group Limited Announces $5 Million Private Placement - PRNewsWire
3 months ago - Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders - PRNewsWire
4 months ago - Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes - PRNewsWire
6 months ago - Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September - PRNewsWire
7 months ago - Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy - PRNewsWire
8 months ago - Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency - PRNewsWire
1 year ago - Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating - Benzinga